{"success":true,"data":{"pressRelease":{"id":"160904","rtpr_id":"nPn793c7Ra-20261005","ticker":"ZYDU","exchange":"NSE India","all_tickers":["ZYDU"],"title":"Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.","author":"PR Newswire","published_at":"2026-10-05T16:42:12.816Z","article_body":"Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.\nPR Newswire\n\nAHMEDABAD, India and PENNINGTON, N.J., Oct. 5, 2026\n\nFirst-to-market launch brings a lower-cost riociguat to U.S. patients living\nwith pulmonary arterial hypertension and chronic thromboembolic pulmonary\nhypertension\n\nAHMEDABAD, India and PENNINGTON, N.J., Oct. 5, 2026 /PRNewswire/ -- Zydus\nLifesciences Limited (Zydus), in partnership with MSN Laboratories Private\nLimited (MSN), today announced the launch of Riociguat Tablets, 0.5 mg, 1 mg,\n1.5 mg, 2 mg and 2.5 mg, in the United States. Zydus and MSN are the first\ncompanies to launch a generic version of Adempas(®) (riociguat) in the U.S.\nmarket. The product was developed and is manufactured by MSN.\n\nRiociguat Tablets are approved by the United States Food and Drug\nAdministration (USFDA) as a generic equivalent of Adempas(®) Tablets in all\nfive strengths. Riociguat is a soluble guanylate cyclase (sGC) stimulator\nindicated for the treatment of adults with persistent or recurrent chronic\nthromboembolic pulmonary hypertension (CTEPH, WHO Group 4) after surgical\ntreatment, or inoperable CTEPH, to improve exercise capacity and WHO\nfunctional class; and for adults with pulmonary arterial hypertension (PAH,\nWHO Group 1), to improve exercise capacity, improve WHO functional class and\nto delay clinical worsening.\n\nCommenting on the development, Dr. Sharvil Patel, Managing Director, Zydus\nLifesciences Limited, said, \"Being first to market with generic riociguat is\na milestone for our U.S. business and for patients with pulmonary\nhypertension. It reflects the strength of our complex-generics pipeline, our\nability to execute day-one launches in specialty categories, and the strength\nof our partnerships that complement our commercial reach in the United States.\nWe are pleased to enable access to the drug across all five strengths,\nallowing physicians and pharmacies to transition patients with confidence.\"\n\nDr. MSN Reddy, Founder & CMD, MSN Laboratories, said, \"Riociguat is a\ntechnically demanding molecule, and bringing the first generic to the U.S.\ndemonstrates the depth of MSN's integrated API and formulation R&D and the\nscale of our manufacturing. Together with Zydus' established U.S. commercial\nplatform, we are confident of delivering consistent, high-quality supply of\nthis important therapy.\"\n\nPAH and CTEPH are rare, progressive and life-threatening conditions in which\npatients typically remain on therapy for life. So far, riociguat was available\nin the United States only as the branded product. Sales of riociguat are not\nreported by IQVIA. According to Bayer's Annual Report 2025, the global sales\nof Adempas(®) were approximately EUR 745 million (approximately USD 850\nmillion) in 2025 (source:\nhttps://www.bayer.com/sites/default/files/2026-03/bayer-annual-report-2025.pdf\n(https://bag-p-001.sitecorecontenthub.cloud/api/public/content/bayer-annual-report-2025-a89e94bdd5294167badb5e532584c3bc?v=3d98b8c0)\n).\n\nAbout Zydus\n\nZydus Lifesciences Ltd., with an overarching purpose of empowering people with\nfreedom to live healthier and more fulfilled lives, is an innovative, global\nlife sciences company that discovers, develops, manufactures, and markets a\nbroad range of healthcare therapies. The group employs over 30,000 people\nworldwide, including 1,500 scientists engaged in R & D, and is driven by\nits mission to unlock new possibilities in life sciences through quality\nhealthcare solutions that impact lives. The group aspires to transform lives\nthrough pathbreaking discoveries. Over the last decade, Zydus has introduced\nseveral innovative, first-in class products in the market for treating unmet\nhealthcare needs with vaccines, therapeutics, biologicals, and New Chemical\nEntities. For more details visit www.zyduslife.com (http://www.zyduslife.com/)\n\nAbout MSN Laboratories\n\nMSN Laboratories Group is a research-driven, fully integrated pharmaceutical\ncompany established in 2003, with a mission to make high-quality medicines\naccessible and affordable worldwide. The group operates 25 manufacturing\nfacilities across India and the USA, supported by a unified R&D ecosystem\nspanning both API and finished dosage development. With over 1,000 patents\nfiled globally, 200+ ANDA submissions and a leading position in US DMF\nfilings, MSN has built a strong global presence. With a portfolio of 550+ APIs\nand 400+ finished dosage forms across 35+ therapeutic areas, MSN serves over\n50 million patients in more than 100 countries. For more details visit\nwww.msnlabs.com (https://www.msnlabs.com/) .\n\nAdempas(®) is a registered trademark of Bayer. All other trademarks are the\nproperty of their respective owners.\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/zydus-msn-partner-to-launch-first-generic-of-adempas-riociguat-tablets-in-the-us-302898651.html\n(https://www.prnewswire.com/news-releases/zydus-msn-partner-to-launch-first-generic-of-adempas-riociguat-tablets-in-the-us-302898651.html)\n\nSOURCE Zydus Lifesciences\n\n\n\nMedia Contact: sujatha.rajesh@zyduslife.com; 91-79-71800000;\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1635476/Zydus-Lifesciences-Limited-Logo.jpg?id=OA2987557\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn793c7Ra-20261005","title":"Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.","author":"PR Newswire","ticker":"ZYDU","created":"2026-10-05T16:42:12.816Z","tickers":["ZYDU"],"exchange":"NSE India","article_body":"Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.\nPR Newswire\n\nAHMEDABAD, India and PENNINGTON, N.J., Oct. 5, 2026\n\nFirst-to-market launch brings a lower-cost riociguat to U.S. patients living\nwith pulmonary arterial hypertension and chronic thromboembolic pulmonary\nhypertension\n\nAHMEDABAD, India and PENNINGTON, N.J., Oct. 5, 2026 /PRNewswire/ -- Zydus\nLifesciences Limited (Zydus), in partnership with MSN Laboratories Private\nLimited (MSN), today announced the launch of Riociguat Tablets, 0.5 mg, 1 mg,\n1.5 mg, 2 mg and 2.5 mg, in the United States. Zydus and MSN are the first\ncompanies to launch a generic version of Adempas(®) (riociguat) in the U.S.\nmarket. The product was developed and is manufactured by MSN.\n\nRiociguat Tablets are approved by the United States Food and Drug\nAdministration (USFDA) as a generic equivalent of Adempas(®) Tablets in all\nfive strengths. Riociguat is a soluble guanylate cyclase (sGC) stimulator\nindicated for the treatment of adults with persistent or recurrent chronic\nthromboembolic pulmonary hypertension (CTEPH, WHO Group 4) after surgical\ntreatment, or inoperable CTEPH, to improve exercise capacity and WHO\nfunctional class; and for adults with pulmonary arterial hypertension (PAH,\nWHO Group 1), to improve exercise capacity, improve WHO functional class and\nto delay clinical worsening.\n\nCommenting on the development, Dr. Sharvil Patel, Managing Director, Zydus\nLifesciences Limited, said, \"Being first to market with generic riociguat is\na milestone for our U.S. business and for patients with pulmonary\nhypertension. It reflects the strength of our complex-generics pipeline, our\nability to execute day-one launches in specialty categories, and the strength\nof our partnerships that complement our commercial reach in the United States.\nWe are pleased to enable access to the drug across all five strengths,\nallowing physicians and pharmacies to transition patients with confidence.\"\n\nDr. MSN Reddy, Founder & CMD, MSN Laboratories, said, \"Riociguat is a\ntechnically demanding molecule, and bringing the first generic to the U.S.\ndemonstrates the depth of MSN's integrated API and formulation R&D and the\nscale of our manufacturing. Together with Zydus' established U.S. commercial\nplatform, we are confident of delivering consistent, high-quality supply of\nthis important therapy.\"\n\nPAH and CTEPH are rare, progressive and life-threatening conditions in which\npatients typically remain on therapy for life. So far, riociguat was available\nin the United States only as the branded product. Sales of riociguat are not\nreported by IQVIA. According to Bayer's Annual Report 2025, the global sales\nof Adempas(®) were approximately EUR 745 million (approximately USD 850\nmillion) in 2025 (source:\nhttps://www.bayer.com/sites/default/files/2026-03/bayer-annual-report-2025.pdf\n(https://bag-p-001.sitecorecontenthub.cloud/api/public/content/bayer-annual-report-2025-a89e94bdd5294167badb5e532584c3bc?v=3d98b8c0)\n).\n\nAbout Zydus\n\nZydus Lifesciences Ltd., with an overarching purpose of empowering people with\nfreedom to live healthier and more fulfilled lives, is an innovative, global\nlife sciences company that discovers, develops, manufactures, and markets a\nbroad range of healthcare therapies. The group employs over 30,000 people\nworldwide, including 1,500 scientists engaged in R & D, and is driven by\nits mission to unlock new possibilities in life sciences through quality\nhealthcare solutions that impact lives. The group aspires to transform lives\nthrough pathbreaking discoveries. Over the last decade, Zydus has introduced\nseveral innovative, first-in class products in the market for treating unmet\nhealthcare needs with vaccines, therapeutics, biologicals, and New Chemical\nEntities. For more details visit www.zyduslife.com (http://www.zyduslife.com/)\n\nAbout MSN Laboratories\n\nMSN Laboratories Group is a research-driven, fully integrated pharmaceutical\ncompany established in 2003, with a mission to make high-quality medicines\naccessible and affordable worldwide. The group operates 25 manufacturing\nfacilities across India and the USA, supported by a unified R&D ecosystem\nspanning both API and finished dosage development. With over 1,000 patents\nfiled globally, 200+ ANDA submissions and a leading position in US DMF\nfilings, MSN has built a strong global presence. With a portfolio of 550+ APIs\nand 400+ finished dosage forms across 35+ therapeutic areas, MSN serves over\n50 million patients in more than 100 countries. For more details visit\nwww.msnlabs.com (https://www.msnlabs.com/) .\n\nAdempas(®) is a registered trademark of Bayer. All other trademarks are the\nproperty of their respective owners.\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/zydus-msn-partner-to-launch-first-generic-of-adempas-riociguat-tablets-in-the-us-302898651.html\n(https://www.prnewswire.com/news-releases/zydus-msn-partner-to-launch-first-generic-of-adempas-riociguat-tablets-in-the-us-302898651.html)\n\nSOURCE Zydus Lifesciences\n\n\n\nMedia Contact: sujatha.rajesh@zyduslife.com; 91-79-71800000;\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1635476/Zydus-Lifesciences-Limited-Logo.jpg?id=OA2987557\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-05T16:42:12.862123636Z","server_sent_at_ms":1791218532862},"received_at":"2026-10-05T16:42:12.913Z","source_url":"https://www.prnewswire.com/news-releases/zydus-msn-partner-to-launch-first-generic-of-adempas-riociguat-tablets-in-the-us-302898651.html"},"analysis":{"id":"149457","press_release_id":"160904","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Zydus Lifesciences, in partnership with MSN Laboratories, launched the first generic of Adempas (riociguat tablets) in the U.S. across all five approved strengths.\n\nMSN developed and manufactures the product; Zydus handles U.S. commercialization through its established platform, with day-one first-mover positioning against a branded franchise that posted roughly $850 million in global sales in 2025.\n\nRiociguat treats pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, lifelong therapies that support durable revenue for first movers.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"First-mover generic launch against an ~$850M branded franchise validates Zydus' complex-generics pipeline and U.S. specialty strategy."},"keyFigures":{"drugName":"Adempas (riociguat)","customDimensions":{"strengths_launched":["0.5 mg","1 mg","1.5 mg","2 mg","2.5 mg"],"branded_global_sales_2025":"approximately EUR 745 million (approximately USD 850 million)"}},"quotedText":"Being first to market with generic riociguat is a milestone for our U.S. business and for patients with pulmonary hypertension.","namedEntities":{"people":[{"name":"Dr. Sharvil Patel","role":"Managing Director, Zydus Lifesciences Limited"},{"name":"Dr. MSN Reddy","role":"Founder & CMD, MSN Laboratories"}],"products":["Adempas","Riociguat Tablets"],"companies":[{"name":"Zydus Lifesciences Limited","ticker":"ZYDU","relationship":"filer / commercial partner"},{"name":"MSN Laboratories Private Limited","relationship":"development and manufacturing partner"},{"name":"Bayer","relationship":"branded originator (Adempas)"},{"name":"USFDA","relationship":"regulator"}],"dollarAmounts":[{"amount":"approximately USD 850 million","context":"global sales of Adempas in 2025 per Bayer Annual Report"}]},"materialImpact":{"score":3,"reasoning":"First-to-market generic launch of Adempas (riociguat) against a ~$850M global branded franchise is a meaningful U.S. revenue opportunity and a demonstration of Zydus' complex-generics first-filer strategy, though first-mover exclusivity may be limited."},"tickerRelevance":{"others":[],"primary":"ZYDU"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"mid-cap pharma","eventGravity":"first-generic-launch vs ~$850M brand","partnershipStructure":"Zydus commercial / MSN manufacturer"}},"event_type":"product_launch","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":3,"narrative":"Zydus Lifesciences, in partnership with MSN Laboratories, launched the first generic of Adempas (riociguat tablets) in the U.S. across all five approved strengths.\n\nMSN developed and manufactures the product; Zydus handles U.S. commercialization through its established platform, with day-one first-mover positioning against a branded franchise that posted roughly $850 million in global sales in 2025.\n\nRiociguat treats pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, lifelong therapies that support durable revenue for first movers.","key_figures":{"drugName":"Adempas (riociguat)","customDimensions":{"strengths_launched":["0.5 mg","1 mg","1.5 mg","2 mg","2.5 mg"],"branded_global_sales_2025":"approximately EUR 745 million (approximately USD 850 million)"}},"named_entities":{"people":[{"name":"Dr. Sharvil Patel","role":"Managing Director, Zydus Lifesciences Limited"},{"name":"Dr. MSN Reddy","role":"Founder & CMD, MSN Laboratories"}],"products":["Adempas","Riociguat Tablets"],"companies":[{"name":"Zydus Lifesciences Limited","ticker":"ZYDU","relationship":"filer / commercial partner"},{"name":"MSN Laboratories Private Limited","relationship":"development and manufacturing partner"},{"name":"Bayer","relationship":"branded originator (Adempas)"},{"name":"USFDA","relationship":"regulator"}],"dollarAmounts":[{"amount":"approximately USD 850 million","context":"global sales of Adempas in 2025 per Bayer Annual Report"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T16:42:21.833Z","global_importance":35,"audience_relevance":30,"importance_components":{"tickerTier":"mid-cap pharma","eventGravity":"first-generic-launch vs ~$850M brand","partnershipStructure":"Zydus commercial / MSN manufacturer"}},"durationMs":8840,"modelName":"glm-5.3-flashx"}}